NORTHROP GRUMMAN CORP /DE/ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NORTHROP GRUMMAN CORP /DE/ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $41.95B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $41.03B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $39.29B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $36.60B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $35.67B | Jan 25, 2024 |
| FY2020 | Dec 31, 2020 | $10.21B | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | $9.08B | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | $8.88B | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | $8.62B | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $8.72B | Jan 28, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $6.63B | Jan 29, 2018 |
| FY2017 | Sep 30, 2017 | $6.53B | Jan 29, 2018 |
| FY2017 | Jun 30, 2017 | $6.38B | Jan 29, 2018 |
| FY2017 | Mar 31, 2017 | $6.27B | Jan 29, 2018 |
| FY2017 | Dec 31, 2016 | $6.40B | Jan 29, 2018 |
| FY2017 | Sep 30, 2016 | $6.16B | Jan 29, 2018 |
| FY2017 | Jun 30, 2016 | $6.00B | Jan 29, 2018 |
| FY2017 | Mar 31, 2016 | $5.96B | Jan 29, 2018 |
| FY2016 | Dec 31, 2015 | $5.69B | Jan 30, 2017 |
| FY2016 | Sep 30, 2015 | $5.98B | Jan 30, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.18B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $4.17B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $2.06B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $4.90B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $7.01B | Jan 25, 2024 |
| FY2020 | Dec 31, 2020 | $330.00M | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | $986.00M | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | $1.01B | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | $868.00M | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | ($409.00M) | Jan 28, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.51B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $4.37B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $2.54B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $3.60B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $5.65B | Jan 25, 2024 |
| FY2020 | Dec 31, 2020 | $1.15B | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | $985.00M | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | $994.00M | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | $934.00M | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | $1.14B | Jan 28, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.10B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.20B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $1.20B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $1.10B | Jan 25, 2024 |
| FY2022 | Dec 31, 2020 | $1.10B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $953.00M | Jan 27, 2022 |
| FY2019 | Dec 31, 2018 | $764.00M | Jan 30, 2020 |
| FY2020 | Jun 30, 2018 | $764.00M | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $639.00M | Jan 30, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.76B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $4.39B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $3.88B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $2.90B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $3.57B | Jan 25, 2024 |
| FY2022 | Dec 31, 2020 | $4.31B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $4.30B | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | $3.83B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $2.61B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $2.81B | Jan 31, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.77B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.78B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $1.44B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $1.42B | Jan 25, 2024 |
| FY2022 | Dec 31, 2020 | $1.42B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $1.26B | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | $1.25B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $928.00M | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $920.00M | Jan 31, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.38B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $49.36B | Jan 27, 2026 |
| FY2024 | Dec 31, 2023 | $46.54B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $43.76B | Jan 25, 2024 |
| FY2022 | Dec 31, 2021 | $42.58B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $44.47B | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | $41.09B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $37.65B | Jan 30, 2020 |
| FY2018 | Dec 31, 2017 | $35.13B | Jan 31, 2019 |
| FY2017 | Dec 31, 2016 | $25.61B | Jan 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.70B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $34.07B | Jan 27, 2026 |
| FY2024 | Dec 31, 2023 | $31.75B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $28.44B | Jan 25, 2024 |
| FY2022 | Dec 31, 2021 | $29.65B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $33.89B | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | $32.27B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $29.47B | Jan 30, 2020 |
| FY2018 | Dec 31, 2017 | $28.00B | Jan 31, 2019 |
| FY2017 | Dec 31, 2016 | $20.36B | Jan 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.67B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $15.29B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $14.80B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $15.31B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $12.93B | Jan 25, 2024 |
| FY2022 | Dec 31, 2020 | $10.58B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $8.82B | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | $8.19B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $7.13B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $5.36B | Jan 31, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.44B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $17.51B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $17.52B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $17.52B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $17.52B | Jan 25, 2024 |
| FY2022 | Dec 31, 2020 | $17.52B | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $18.71B | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | $18.67B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $12.46B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $12.45B | Jan 31, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.66B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $15.30B | Jan 27, 2026 |
| FY2024 | Dec 31, 2023 | $14.77B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $15.31B | Jan 25, 2024 |
| FY2022 | Dec 31, 2021 | $12.91B | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | $10.48B | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | $8.75B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $8.07B | Jan 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.91B | Jan 31, 2019 |
| FY2017 | Dec 31, 2016 | $10.63B | Jan 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.40B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $4.35B | Jan 27, 2026 |
| FY2023 | Dec 31, 2023 | $3.11B | Jan 25, 2024 |
| FY2023 | Dec 31, 2022 | $2.58B | Jan 25, 2024 |
| FY2023 | Dec 31, 2021 | $3.53B | Jan 25, 2024 |
| FY2023 | Dec 31, 2020 | $4.91B | Jan 25, 2024 |
| FY2022 | Dec 31, 2019 | $2.25B | Jan 26, 2023 |
| FY2021 | Dec 31, 2018 | $1.58B | Jan 27, 2022 |
| FY2020 | Dec 31, 2017 | $11.23B | Jan 28, 2021 |
| FY2019 | Dec 31, 2016 | $2.54B | Jan 30, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.70B | Jan 27, 2026 |
| FY2024 | Dec 31, 2024 | $16.27B | Jan 30, 2025 |
| FY2023 | Dec 31, 2023 | $13.86B | Jan 25, 2024 |
| FY2022 | Dec 31, 2022 | $12.88B | Jan 26, 2023 |
| FY2021 | Dec 31, 2021 | $12.78B | Jan 27, 2022 |
| FY2020 | Dec 31, 2020 | $15.00B | Jan 28, 2021 |
| FY2019 | Dec 31, 2019 | $13.88B | Jan 30, 2020 |
| FY2018 | Dec 31, 2018 | $14.40B | Jan 31, 2019 |
| FY2017 | Dec 31, 2017 | $15.27B | Jan 29, 2018 |
| FY2016 | Dec 31, 2016 | $7.07B | Jan 30, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29 | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | 28 | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | 13 | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | 31 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 43 | Jan 25, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | 5 | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | 5 | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | (2) | Jan 28, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 29 | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | 28 | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | 13 | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | 31 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 43 | Jan 25, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Jan 28, 2021 |
| FY2020 | Sep 30, 2020 | 5 | Jan 28, 2021 |
| FY2020 | Jun 30, 2020 | 6 | Jan 28, 2021 |
| FY2020 | Mar 31, 2020 | 5 | Jan 28, 2021 |
| FY2020 | Dec 31, 2019 | (2) | Jan 28, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 142.00M | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | 144.95M | Jan 27, 2026 |
| FY2024 | Dec 31, 2023 | 150.11M | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | 153.16M | Jan 25, 2024 |
| FY2022 | Dec 31, 2021 | 156.28M | Jan 26, 2023 |
| FY2021 | Dec 31, 2020 | 166.72M | Jan 27, 2022 |
| FY2020 | Dec 31, 2019 | 167.85M | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | 170.61M | Jan 30, 2020 |
| FY2018 | Dec 31, 2017 | 174.09M | Jan 31, 2019 |
| FY2017 | Dec 31, 2016 | 175.07M | Jan 29, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.29B | Jan 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.19B | Jan 27, 2026 |
| FY2025 | Dec 31, 2023 | $1.12B | Jan 27, 2026 |
| FY2024 | Dec 31, 2022 | $1.05B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $983.00M | Jan 25, 2024 |
| FY2022 | Dec 31, 2020 | $953.00M | Jan 26, 2023 |
| FY2021 | Dec 31, 2019 | $880.00M | Jan 27, 2022 |
| FY2020 | Dec 31, 2018 | $821.00M | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $689.00M | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $640.00M | Jan 31, 2019 |